Cargando…

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain

The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) presents many public health challenges, including a substantial impact on healthcare resource utilization and costs. There are important regional differences in the burden of NAFLD/NASH, and Spa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Romero-Gomez, Manuel, Kachru, Nandita, Zamorano, Meritxell Ascanio, Darba, Josep, Shreay, Sanatan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7738099/ https://www.ncbi.nlm.nih.gov/pubmed/33327291 http://dx.doi.org/10.1097/MD.0000000000023506

Ejemplares similares

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
por: Younossi, Zobair M., et al.
Publicado: (2023)

Use of a Diabetes Self-Assessment Score to Predict Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Kim, Gyuri, et al.
Publicado: (2015)

Clinical and sociodemographic determinants of disease progression in patients with nonalcoholic steatohepatitis in the United States
por: Ruiz-Casas, Leonardo, et al.
Publicado: (2021)

Efficacy and safety of acetyl-CoA carboxylase (ACC) inhibitors in the treatment of nonalcoholic steatohepatitis (NASH): A protocol for systematic review
por: Xu, Liubin, et al.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
por: Wen, Xuerong, et al.
Publicado: (2021)

Therapeutic Effects of microRNAs on Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review and Meta-Analysis
por: Zhu, Yuezhi, et al.
Publicado: (2023)

Nonalcoholic steatohepatitis: A scientometric analysis of publications during 1980–2018
por: Trifan, Anca, et al.
Publicado: (2019)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database
por: Boursier, Jérôme, et al.
Publicado: (2020)

Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B
por: Liu, Liang, et al.
Publicado: (2019)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database
por: Terai, Shuji, et al.
Publicado: (2021)

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis
por: Sawangjit, Ratree, et al.
Publicado: (2016)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

Exosomal microRNAs and Progression of Nonalcoholic Steatohepatitis (NASH)
por: Qi, Xiaoyan, et al.
Publicado: (2022)

353. A Comparison Study of Prevalence and Risk Factors for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by Transient Elastography (TE) in HIV-Infected Patients
por: Choe, Sunny, et al.
Publicado: (2019)

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)
por: Murphy, William A., et al.
Publicado: (2022)

Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma
por: Kutlu, Ozlem, et al.
Publicado: (2018)

A new method to induce nonalcoholic steatohepatitis (NASH) in mice
por: Savari, Feryal, et al.
Publicado: (2019)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Nonalcoholic Fatty Liver Disease for Identification of Preclinical Carotid Atherosclerosis
por: Sinn, Dong Hyun, et al.
Publicado: (2016)

Risk factors of nonalcoholic fatty liver disease in healthy women
por: Guan, Hui, et al.
Publicado: (2023)

Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients
por: Tai, Chi-Ming, et al.
Publicado: (2016)

Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis
por: Zhou, Xiangyu, et al.
Publicado: (2023)

Development of de novo nonalcoholic fatty liver disease following pancreatectomy
por: Patel, Vanisha, et al.
Publicado: (2023)

The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease
por: Chuang, Te-Jung, et al.
Publicado: (2023)

Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH)
por: Yoneda, Masato, et al.
Publicado: (2008)

Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults
por: Pierre, V, et al.
Publicado: (2017)

Imaging Fibrogenesis in a Diet-Induced Model of Nonalcoholic Steatohepatitis (NASH)
por: Hartimath, S. V., et al.
Publicado: (2019)

Hepatic Molecular Signatures Highlight the Sexual Dimorphism of Nonalcoholic Steatohepatitis (NASH)
por: Vandel, Jimmy, et al.
Publicado: (2020)

The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression
por: Li, Xinzhi, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure
por: Valbusa, Filippo, et al.
Publicado: (2016)

Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean
por: Oh, Yun Hwan, et al.
Publicado: (2023)

Association of resting heart rate with nonalcoholic fatty liver disease in postmenopausal women
por: Kim, Hong-Bae, et al.
Publicado: (2020)

A nomogram incorporated lifestyle indicators for predicting nonalcoholic fatty liver disease
por: Peng, Kaili, et al.
Publicado: (2021)

Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases
por: Wong, Robert J., et al.
Publicado: (2021)

The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_krfp43va0eqgnukmqjr9k0t329